REGN|Regeneron Pharmaceuticals Inc|Preço:759.180|Var. %:4.16

Mais detalhes de Regeneron Pharmaceuticals Inc Empresa

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.

Informações de Regeneron Pharmaceuticals Inc



Código da empresaREGN

Nome da EmpresaRegeneron Pharmaceuticals Inc

Data de listagemApr 02, 1991

CEOSchleifer (Leonard S)

Número de funcionários15106

Tipo de títulosOrdinary Share

Fim do ano fiscalApr 02

Endereço777 Old Saw Mill River Road

CidadeTARRYTOWN

Bolsa de valoresNASDAQ OMX - NASDAQ BASIC

PaísUnited States of America

Código postal10591

Telefone17813705000

Sitehttps://www.regeneron.com/

Código da empresaREGN

Data de listagemApr 02, 1991

CEOSchleifer (Leonard S)

Executivos da empresa Regeneron Pharmaceuticals Inc



Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

21.78K

+2035.00%

Mr. Arthur F. (Art) Ryan

Independent Director

17.81K

+155.00%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.49K

+119.00%

Dr. Michael S. Brown, M.D.

Independent Director

12.77K

+155.00%

Ver Mais

Nome

Nome/Posição

Posição

Ações detidas

Variação

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.13M

+14941.00%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

688.05K

+17578.00%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

52.18K

-2213.00%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

44.85K

+1080.00%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.17K

-743.00%

Mr. George L. Sing

Independent Director

33.06K

+155.00%

Detalhamento da receita

Moeda: USDAtualizado em: ter, 6 de jan

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por EmpresaUSD

Nome

Receita

Proporção

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Outro

462.20M

12.31%

Os dados relevantes ainda não foram divulgados pela empresa.

Por Empresa

Por Região

Por EmpresaUSD

Nome

Receita

Proporção

Sanofi

1.62B

43.07%

EYLEA

680.60M

18.13%

EYLEA HD

430.60M

11.47%

Bayer

344.80M

9.18%

Libtayo

219.10M

5.84%

Outro

462.20M

12.31%

Distribuição de ações

Atualizado em: dom, 16 de nov

Investidores

Tipos de investidores

Investidores

Proporção

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Outro

74.18%

Investidores

Proporção

The Vanguard Group, Inc.

8.73%

BlackRock Institutional Trust Company, N.A.

5.29%

State Street Investment Management (US)

4.54%

Dodge & Cox

4.41%

JP Morgan Asset Management

2.85%

Outro

74.18%

Tipos de investidores

Investidores

Proporção

Investment Advisor

45.29%

Investment Advisor/Hedge Fund

31.13%

Hedge Fund

5.04%

Pension Fund

2.77%

Research Firm

2.72%

Bank and Trust

2.20%

Individual Investor

2.07%

Sovereign Wealth Fund

1.23%

Insurance Company

0.20%

Outro

7.36%

Participação acionária institucional



Atualizado em: qui, 1 de jan

Período do relatório

N.º de instituições

Ações detidas

Proporção

Variação

2025Q4

2674

93.48M

90.51%

-2.18M

2025Q3

2596

94.26M

91.26%

-4.21M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

Ver Mais

Atividade dos acionistas



Nome

Ações detidas

Proporção

Variação

Var. %

Data

The Vanguard Group, Inc.

9.00M

8.71%

-376.36K

-4.02%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

5.46M

5.29%

-204.21K

-3.60%

Sep 30, 2025

State Street Investment Management (US)

4.69M

4.54%

-140.78K

-2.91%

Sep 30, 2025

Dodge & Cox

4.55M

4.41%

+724.56K

+18.94%

Sep 30, 2025

JP Morgan Asset Management

2.95M

2.85%

+130.73K

+4.64%

Sep 30, 2025

Geode Capital Management, L.L.C.

2.54M

2.46%

+70.84K

+2.87%

Sep 30, 2025

Invesco Capital Management (QQQ Trust)

2.32M

2.24%

+133.61K

+6.12%

Dec 31, 2025

Putnam Investment Management, L.L.C.

2.15M

2.08%

+117.43K

+5.78%

Sep 30, 2025

Capital World Investors

2.00M

1.93%

+32.35K

+1.65%

Sep 30, 2025

Loomis, Sayles & Company, L.P.

1.98M

1.92%

+38.38K

+1.98%

Sep 30, 2025

Ver Mais

ETFs Relacionados



Atualizado em: sáb, 6 de dez

Nome

Proporção

ProShares Ultra Nasdaq Biotechnology

6.6%

Invesco Nasdaq Biotechnology ETF

6.55%

Amplify Weight Loss Drug & Treatment ETF

6.4%

iShares Biotechnology ETF

5.9%

Simplify Health Care ETF

5.54%

VanEck Biotech ETF

5.51%

Invesco Biotechnology & Genome ETF

5.4%

iShares Genomics Immunology and Healthcare ETF

4.97%

First Trust NASDAQ Pharmaceuticals ETF

4.36%

First Trust NYSE Arca Biotechnology Index Fund

3.88%

Ver Mais

ProShares Ultra Nasdaq Biotechnology

Proporção6.6%

Invesco Nasdaq Biotechnology ETF

Proporção6.55%

Amplify Weight Loss Drug & Treatment ETF

Proporção6.4%

iShares Biotechnology ETF

Proporção5.9%

Simplify Health Care ETF

Proporção5.54%

VanEck Biotech ETF

Proporção5.51%

Invesco Biotechnology & Genome ETF

Proporção5.4%

iShares Genomics Immunology and Healthcare ETF

Proporção4.97%

First Trust NASDAQ Pharmaceuticals ETF

Proporção4.36%

First Trust NYSE Arca Biotechnology Index Fund

Proporção3.88%

Dividendo



Um total de 0.00 USD foi distribuído em dividendos nos últimos 5 anos.

Data

Dividendo

Data de registro

Data de pagamento

Data ex-dividendo

Jan 30, 2026

REGN.NB Interim Cash Dividend of gross USD 0.94 paid on Mar 05, 2026 going ex on Feb 20, 2026

Feb 20, 2026

Mar 05, 2026

Feb 20, 2026

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

Desdobramento de ações



Data

Data ex-dividendo

Tipo

Proporção

Sem dados

Data

Data ex-dividendo

Tipo

Proporção

Sem dados